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~4~nttro~~rhr, Ybwroro 
unsedated, awaaks &o&s. Studier were performed in I?. 
chronicatl~ instrumented animal! in which a surgically 
inqklltcd etcctromsgnctic Row probe an.3 insamranary 
mtheter sttourd mes~re,,,cnt 01 t&t cirrulnt,ox mronary 
blood Row during intraarterial admtntotratlon OF the atrial 
natriurotic ppttdor. 
Bolus doses of both human atrial oatriuretic oeotide and 
rat slriopeptin II produced doEe.dependent c&&q vnso. 
dilaiion; :he lhrekdd lo: mronary wx!dils!$n was 0.2 
The atrial natriuretic oerrtidea are ~a~~a~ti~e oolvocotide 
hormooes that cause ~el&atmn of prcconnlrictkd &dar 
arips (l.2). increase renai blood flaw after intraarterial 
administration (3) and cause decreased forearm vascular 
resistance in humans (4). However, Wangler et al. (5) 
reported that atriopeptin II had a profound coronary vase- 
constrictor &cl in both a LangendortT-perfused guinea pig 
heart model and in a blood-perfused open chest canine 
model. In comrast, in a preliminary study lb1 we found tha: 
intrawterial human atrial natnuretic peptide reduced coro- 
nary resistance in a constam Row xute canine model. 
Burnett et al. (7) Found either no effect or transient coronary 
vasodilation m response to systemic administration of atrial 
natriuretic peplide to anesthetized dogs as well as in an 
isolated LangendortT-perfused rat heart preparation. 
General anesthesia and SCUIC surgical trdoma cause im- 
portent perturbations of the coronary circulation that may 
alter responses to subsequent experimental interventions 
(8). Consequently, this study examined the cffeots of atria! 
natriuretic peptide on the coronary circolation in a chroni- 
cally instrumented, awake canine model. In addition to 
documenting the response of the coronary circulation to 
atria1 natriuretic peptide, studies were performed to deter- 
mine whether the vasomotor properties of atrial natriuretic 
peptide involved adenosine or cyclooxygenase.dependent 
mechanisms. 
Methods 
Animal instrumentation and surgical preparation. Twelve 
adult mongrel dogs weighing 24 to 30 kg were se&ted with 
fentanyl citrate (0.4 mg intramuscularly and drop&do1 (20 
mg intramuscularly). anesthetized with sodium penloharbital 
I30 mdkg intravenously). intubated and ventilated with a 
respirator. Under sterdc conditions, a left thoracotomy was 
performed in the fifth intercostal space and a 3.0 mm outer 
diameter heparin-filled polyvinyl chloride catheter was intro- 
duced into the left internal thoracic artery and advanced into 
the ascending aona. A pericardial cradle was formed and a 
second catheter was inserted into the left ventricle through 
the left ventricular apex and tie? io nlace with a purse-string 
suture. A similar catheter WI inserted mto !hc left ,~trwm 
through the atria1 appendage .Thc proyunrd left circumflex 
coronary alter” was drwxied tree .,lld a Howe,, HSR 
electromagnetic nowmeter prohc (Howell Instrummw wh 
fitted around the artery. A 2.7 mm outer d,amctcr hydraulic 
occluder constructed of polyvinyl chlorrdc tubinp wa\ Btlsd 
around +.c artery distal to thr Rowmeter probe. Finally. ,i 
catheter constructed of a 5 cm len@b of Sllastlc lubing with 
an internal diameter oi 0.3 mm bondrd to il laiger Sda\tc 
tubing with an internal diameter 01 I.6 mm was introduced 
into the left weumflcx corwary artery )u” dwut to the 
hydraulic occtudcr after the method of Gwirtr (91 ‘The 
pericardium was loosely clowl. all cathctcn and elec!rical 
leads were broupht out bewecn the ribs. runneled wbcota. 
neously and exited through the \kin at the base of the neck. 
Tbe dogs were allowed 7 to IU days to recover before beinK 
studied. Catheters were flushed dally with hcparm. 
Srudy Prorocol 
On the day of study. the dogs were placed in a sling and 
allowed to adjust to laboratory conditions for i h before 
study. Aortic and left ventricular pressures. Icft vcrtr~cular 
mea” rate of prcwre rise IdPidt) and coronary blood Rnw 
were recorded continuously on an eight channel d$rcct- 
writing oscillogr& (Hewlett-Packard model X8OUI. 4omc 
and left ventricular prcssurcs were obtained usmg Statham 
P231D pressure transducers. Coronary artery blood Row was 
measured with a Statham SP2202 electromagnetic tlou- 
meter. Flowmeter probes were calibrated in vitro using 
norm.4 saline wlution. 
Cmus 1. Grow 1 consisted of eieht does in which the . 
effect of human atrial natriuretic peptide larginme- 
IOZ-tyrosine-126) was studied. Atrial natriuretic pepttde was 
diluted in lactated Ringer solution with bovine serum albu- 
mitt so that doses of O.OtXOZ. 0.CW2.0.002.0.02.0.2.2.0 and 
10.0 &kg could be deliver&l in a ~olumc ofO.5 ml. Daes of 
atrial natriuretic pcptide wcrc injected ssqucnt~+lty into the 
coronary artery eathctcr over a period of 5 E and the 
response was observed. Coronary Row was allowed to 
return to the preinjection control value before each rubse- 
quent injection of atrial nittnuretic prptide; at least I mm 
was allowed between injections. The rcsponx to an equal 
volume of vehicle was observed before and after the atrmt 
natriurctic peptide respanscr. 
receptor blockade was no longer prcwnt as dcmonamtcd by 
return to control level? of the coronary vowdilator rc\powe 
i” ~ideno\me. 
Irrdumrllro< m (5 mglkg Intrawnowiyl was the” .&nini,- 
tered to delcrmine whether the coronary vasodilatian pro- 
duced by atrial natriuretic peptcdc mvolvcd pro%glandin- 
dcpcnilent mechanisms. Cyclooxygenax inhlbltion wia 
documented by demonstratirig that the mcreax in conmary 
Row produced by admimstrwwo of arachldonlc acid WO to 
500 1.0 ii< iin rorracoronary bolos injection) w:~b attenuated 
after mdumclhacin admimstration. The ;c~ponse to z.tn;d 
sxlr~urct~c peatide was again ub\crved after indomethaein. 
(:roup It. The effects of the 23.ammo acid rat atrio?cp- 
tm II Ci~:ma Chemical) WPF studied in four dogs I” Group II. 
Alriopeotm II was dtisolxd !n warm 0.05 .H acetic ucld and 
lhen dliutcd in 0.9% wdium chlcride FO that doses of 0.02. 
0.2 and 2.0 weike could be delivered in Q vutume cf 0.5 ml. 
Bolur dew; if vehicle or atriopcpnn Ii were injected w- 
quent~ally into the coronzry artery over 5 sand the responw 
obwved as ,n Group I. 
Data anal~r~ and statistics. Aorl~ and left vcntricutar 
Pressure, ad coronary blood “ow wcrc mcawred at the 
time of the peak rcsponsc of coronary hlaod Row to each 
alnal natrwrctie peptidc injcetion. Time to peak Row re- 
sponw and duration of flow response were mcawrrd from 
the oract of mjcction. Mean coronary vawdar rcs~stancc 
wan calculated as mean aortic pressure i coronary bkcd 
How. Late dmstolic coronary reststance was computed as 
late draadi; aortic pressure law dtastntic coronary blood 
Row on a beat by heat basis. Late dia\tulic prwcurc asd flow 
mcasurcmcntc were taken at 90% through the cardiac cycle 
measured from the beginning of the rise of the pontivc dP/dt 
tracing. Hcmodynamic data before and after rach mterven- 
tmn were compared with one-way analysis of variance 
(ANOVAl. when a p YPIUS ri co.05 was found, indiwdual 
comparv~n~ were performed usin Duncan’\ 1~91. Rerutt~ 
arc prccented as mean z WM. 
Results 
The rcwonsc to human atrial natriwcuc pepode was 
phenyltheophylline I!? mglkg intrdenouslyl; IO min after evaluated iA eight dog5 and the cKccts ofadcnosmc rcccptor 
administration, when all oreswrc~ and coronary blood flow blockade with 8.phcnyl!hcophylline and cyclooxyge~asc m- 
had returned to basclinc’valuca. adenoaine &ptor block- hibirion with indomethacin were studied in scvcn doga. The 
ade was documented by drmonWzzting at least 95% inhibi- effect of anal natrioretlc peptide on late diastolic coronary 
lion of the increase in coronary Row that occurred m rcwtancc aas wessed in five doga during control condi- 
lions and ;1Ttcr B-phcnyltheophylline admimstratmn. and in 
tour dogs ~iier mdomethaci~ adminisrrauon. 
Hemcdynamie effecLs (Table I). Mean aolfic pressure. left 
ventricular svstolic and end-diastolic D~CWIRS. left ventric. 
ular dl’ldt and he:xt rate did not change abler intracoronary 
injeclion of vehxle or any dose of human alrial nalriuretic 
pepiide Vahlc IL Though thcrc ws a trend toward a 
dccicaw in hurl WC and mean aurtic DKSSUK during the 
coxx of the study. neither achieved s&stical significance. 
Coronary et&& (Table I, Fig. Il. Mean and late diastolic 
coronary resistance ~atucs wcrc significantly reduced and 
coronary blood Row W;II significantly mcreased by doses of 
atrial natriurettc peplide 20.2 &kg. Lale diaslolic coronary 
vascular resistance parallelrd that of total coronary resis- 
inuci. Th; dccreascs in coronary ES.. I ‘=twce and i!x?S+?S in 
coronary flow were directly related lo the dose of alrial 
natriuretic peptide. with a 61% increase in peak coronary 
blood Row at the highest dose (IO fig/kg). No increase in 
coronary resistance or decrease in coronary blood flow was 
obxrved at any time in response to any dose of atrial 
natriuretic peptide used in this study. The time to the peak 
Row response wups 5.5 i 0.3, 7.9 * 0.5 and tn.4 I I .7 5 for 
atrial natriurelic peptide doses of 0.2, 2.0 and 10.0 &g/kg. 
respectively. The duration of the increase in flow was 14.4 + 
l.3.20.6+2.land25.6+4.8sf0rdosesof0.2.2.0aad10.0 
&kg. respectively. 
Adenosine blwkade and cydwxygenase inhibition (Fig. I). 
Neither R-phenyltheophylline nor indomethacin caused a 
significant change in heart r&c. aortic pressure. left ventric- 
ular systolic or end”diastolic twessores. comnarv blood Row 
or coronary vascular resist&. The rcspon~ to atrial 
natriurelic peptidc was not significantly altered by either 
I-phenytheophylline or indomethacin. In addition, the time 
to the peak flow response and the duration of the Row 
response were not different after 8.phenyltheophylline or 
indomethacin. 
Group II fTub/e 2. rig. 2,t 
Hearl rale. mean aorlic pressure. IeR ventricular systolic 
and diastolic ~r.?rawc and lefl venlricolar dP/dt did not 
change signilicantly inresponz toany dose ofatriopeptm II. 
Mean and late diastolic coronary resistance decreased sig- 
nificantly at doses of 0.2 and 2.0 &kg of atrioprptin II. and 
coronary blood Row increased 102% at a dose of 2.0 &kg. 
The time to peak Row was 6.4 i- 0.2 and 10.4 + 2.3 sand the 
duration ofincreased Row was IO.9 ? 0.4 and 26.5 c 6. I s for 
doses of 0.2 and 2.0 pg/kg, respectively. No increase in 
coronary resistance or decrease m coronary blood Row was 
observed at any woe m response to atriopeptin It. 
alter reflex conlrol of the coronary vawIBr bed 18.1!-11) 
ACUE coronary disscctmn can alter connary vdsorn~t~r 
tone and autoregulatory rcspanses ,151. Progresswe IOF\ of 
autoreguladon may occur with time in the cannuiatcd. per- 
fused coronary prepxation (16, The,r perturhsrion, miry 
modify responses tu subsequent erpenmrntal interventmm 
For this reason. the wesent sludv exammed the clfecr~ of 
atrial natriurctic &tides on lhc coronary circulatmn m 
chronically instrumented awake ammals thal were free from 
the cffccts of gcncral ancsthcria and acute wrg~al frauma 
Coronary &r& of atrial n&iur& peptides. :n the 
awake dog. both human atrial nafriurebc pcptide and atrin- 
peptin II caused transient dose-related mcrcases of coronary 
blood Row at doses of 20.2 &kg. Thin threshold dose for 
coronary vasodi!ation corresponded 10 a conwnlralion of 
approximately 80 n&/g of myocardaum. Although we (61 
vascular lone WE produced by pretreatment with a YBIU- 
constrictor. atrial nalriurelic peplide cawed a marked de- 
creae in renal resistance 131. 
In Ihe LangendorK-perfused gined pig hart prepam!mn 
used by Wangler et 81. (51, hasal coronary vasodilauon 13 
prrrcnt hccau\c Ihe limited oxygen-carryinp cupacoty of Ihe 
perfurate requres hfh Row ra!e\. In conl:4~l 10 Ihi, hasal 
coronary wiwdilafion in the Lanpendomprepamtion. vaw- 
mowx mne 15 high in the intact coronwy syslem. Although 
curonary svaodilation dunng basal conditions might impalr 
further vawddation in response 10 alrmpeplm II. coronary 
vasoddaror re\erve was not exhauad m Ihc Langcndofl 
pcrfwion ,y\tcm used by Wangler CI al. 1% as mdxated by 
further vawdMion in rc\pon\c 10 adenosme Infusion. In 
addilmn. there investigators also reported that alrmpeptin II 
produced wronary vasoconwictic~ in an aneathettzcd open 
chest blood-perfused canine coronary perlusmn Wem. 
-1 hrce rcuk+ xc in ~ontrasI to our prerenl fmdmgs and 
,ho,e of Burnslt cf al. 171. *ho :ound rahsr no effccr or a 
thnre of &m,ler el id. 0). 
Varodilator potenr). The 2.5 amino acid human atrial 
o3lnurcuc pepI& Iarg~ninc-l02-~yro~~nC_12h alrial oati. 
ureoc pqxidct and Ihc 23 amino xid m1 u!riopeptin II 
(cenne.lOi-;trgin,n~f2~, wcrc employed in out study. Lack 
ofthe C-tc!minal tyroGnc in afriopepfin 11 has been reported 
(171 lo rewh in ICI\ varorelaxwd activity than occurs with 
the tyrocinc-l?f+coolaming human atrial nalriurelic peptide. 
Haccvcr. m our study. the thrcrhold for coronary varodi- 
bation wr h,milar for tbc IWO peptides and [here was Q 
tendency for greater vasodilaliun with atriopeprin II. The 
plasma conceotmtions of human atria1 natriurelic pcptidc 
and a!riopcptin II ~1 the threshold dose for corosary vabo- 
dilation in our study were estimated lo be I &n?l. which is 
sub*tamially greater than Ihe reported (181 physiologic 
plasma lcvelr of atria1 natriure\ic pepdde in normal humans 
(20 to 60 p$rnl) and paticntr wth chronic congcilivc heart 
f&w cl53 io XK! p&IL Thus. coronary vasodilation 
occurred at pharmacologic do,er, whereas no response was 
rccn RI doses wmlar 10 phyrmlogic levels. 
Adenocine receptor blockade. Adenosinc is a potent 
cndogenous coronary vesoddator. To determine whether d 
might pnnicipae in the coronary vasodilalion producd by 
ainal natnurciic pepddc, the coronary blood flow response 
10 humln &al n&w&c peptide was observed after ad- 
mioistralion of the polen! adenosine receptor antagonist 
8.phenylfheophyllinc (19.20). The rcspoose 10 alrial oalri- 
uretic peplide was not impaired by adenosine receptor 
blo&a&. dwwu~iwit~g ilair; coronary iasodilalioxi was not 
medialed lhraugh WI adenorinp-dependent mechanism. Ad- 
eqwcy of adenoiine receptor blockade was confirmed by 
demonairaung marked attenuation of the response lo aden- 
“sine even a1 doses fhal caused greater increases in coronary 
blood Row fhan ‘bone produced by the highest dose of atrkal 
natriurctic pcptide. 
Qcloorygenase inhbWon. Coronary vascular tissue can 
syntheGzr prouaglandina. a,? vasoactivc nrachidonic acid 
mclahoint 5 may contribute 10 trx regulation of coronary 
Row 121) Cycloo~ygmase inhibition has been reported to 
blwt 1221 or have litlle effect (23.24) on the coronary 
vawdalator response to hypoxia and irchemia. The elect of 
cyclooxyg~na~e inhibmon was mverligaled by comparing 
tht rc\pon,e ID .&al nawioretic peptide before and after 
indomr:hacin. Thr- response to atrial nabiurcdc peptide was 
unchanged afrer mdomclhncin, dcmonarraling that coronary 
vwdilalion did not utiluc a pruslaelandin-depen(l~o[ mech- 
sm\m. Thir findow is consonan! with similar rew:ts obtained 
in \hun-term camnc studier (71 a~ well ah in in vitro stud& 
uGsp i>olalcd vaxular atrips C Il. 
Conclurinns. Both human slrial nidriurcdc peptide and 
rat alriopeplin II cawed transient va\odilation of the coro- 
nary rcwhnce YCEICIS in Ihc in?act awake animal: coronary 
wsoconslricfion was neverobwvcd. Coronary vasodilation 
occurred only with phermacologic doses of atria1 nalriurelic 
pcplide thal produced computed plasma concentr!ations 
grealcr than those previously measured during physiologic 
condilions. These Apdings do not ruppon an important role 
for atrial n&or& peptide in conrrol of coronary blood 
Row. 

